Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Barbara Balogh has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    In Vitro Investigation of Tapinarof-Loaded Nanogels in an Imiquimod-induced HaCaT–THP-1 Co-Culture Model

    by Barbara Balogh, Ágnes Klusóczki, Ágota Pető, Pálma Fehér, Zoltán Ujhelyi, Judit Váradi, Ildikó Bácskay


  • Open Access

    Tapinarof Nanogels as a Promising Therapeutic Approach

    by Barbara Balogh, Ágota Pető, Pálma Fehér, Zoltán Ujhelyi, Ildikó Bácskay

    Psoriasis is a chronic inflammatory skin disease characterised by increased oxidative stress, the overproliferation of keratinocytes, the accumulation of inflammatory mediators, and skin barrier damage. Although a number of therapeutic options are available, finding long-term treatments that are well-tolerated and patient-friendly treatments remains a challenge. Tapinarof is a new type of aryl hydrocarbon receptor (AhR) modulator that has recently attracted attention as a promising non-steroidal alternative. However, its application may be limited by its poor water solubility and low degree of skin penetration. Nanotechnology-based drug carriers, specially nanogels, offer new opportunities to overcome these limitations by combining the advantages of targeted drug delivery and enhanced skin penetration. Furthermore, nanogel formulations can improve skin hydration and support the restoration of skin barrier function, which are important in the treatment of psoriasis. This review focuses on current and emerging therapeutic approaches, with particular emphasis on the potential of incorporating tapinarof into nanogel formulations as a novel alternative to topical psoriasis treatment.


  • Open Access

    Formulation and Evaluation of Different Nanogels of Tapinarof for Treatment of Psoriasis

    by Barbara Balogh, Ágota Pető, Ádám Haimhoffer, Dávid Sinka, Dóra Kósa, Pálma Fehér, Zoltán Ujhelyi, Monica Argenziano, Roberta Cavalli, Ildikó Bácskay

    Psoriasis is an immune-mediated skin condition. There are many therapeutic options for its treatment; however, none of them is completely effective. Tapinarof is a promising new active substance; it was recently approved by the FDA for the treatment of psoriasis. The aim of our study was to prepare topical nanoformulations of the active substance to improve its bioavailability and therapeutic effect. The biocompatibility investigation of the formulations was carried out by MTT assay, and the size distribution of the preparations was investigated by DLS. In parallel, the rheological properties and the texture were examined, and the in vitro release of tapinarof was assessed by the Franz diffusion method. An in vitro wound healing assay was also carried out to study the drug’s properties. Our results show that the preparations were safe on HaCaT cells. The particle size of the formulations was proven to be in the nanoscale range. In the in vitro release studies, nanogel II. showed greater release of the active substance. According to the wound healing assay, incorporation of the drug into nanoformulations increases the antiproliferative and antimigration activity of the drug. Overall, nanoformulations of tapinarof were successfully prepared, and our results suggest that they can be a useful addition to the current therapeutic practice of psoriasis.